158 related articles for article (PubMed ID: 9283714)
1. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Jackson HC; Needham AM; Hutchins LJ; Mazurkiewicz SE; Heal DJ
Br J Pharmacol; 1997 Aug; 121(8):1758-62. PubMed ID: 9283714
[TBL] [Abstract][Full Text] [Related]
2. 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
Thomas GH; Babbs AJ; Chatfield RE; Krülle TM; Widdowson PS; Provost D; McCormack JG
Obesity (Silver Spring); 2009 Mar; 17(3):467-73. PubMed ID: 19219064
[TBL] [Abstract][Full Text] [Related]
3. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC
Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat.
Jackson HC; Bearham MC; Hutchins LJ; Mazurkiewicz SE; Needham AM; Heal DJ
Br J Pharmacol; 1997 Aug; 121(8):1613-8. PubMed ID: 9283694
[TBL] [Abstract][Full Text] [Related]
5. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors.
Lane EL; Cheetham S; Jenner P
J Pharmacol Exp Ther; 2005 Mar; 312(3):1124-31. PubMed ID: 15542624
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents.
Heal DJ; Cheetham SC; Prow MR; Martin KF; Buckett WR
Br J Pharmacol; 1998 Sep; 125(2):301-8. PubMed ID: 9786502
[TBL] [Abstract][Full Text] [Related]
7. Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus.
Smith JE; Lakoski JM
Synapse; 1998 Nov; 30(3):318-28. PubMed ID: 9776135
[TBL] [Abstract][Full Text] [Related]
8. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
Tallett AJ; Blundell JE; Rodgers RJ
Behav Brain Res; 2009 Mar; 198(2):359-65. PubMed ID: 19061919
[TBL] [Abstract][Full Text] [Related]
9. Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
Wellman PJ; Jones SL; Miller DK
Pharmacol Biochem Behav; 2003 Apr; 75(1):103-14. PubMed ID: 12759118
[TBL] [Abstract][Full Text] [Related]
10. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
Gundlah C; Martin KF; Heal DJ; Auerbach SB
J Pharmacol Exp Ther; 1997 Nov; 283(2):581-91. PubMed ID: 9353373
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia.
Raiteri M; Bonanno G; Vallebuona F
J Pharmacol Exp Ther; 1995 May; 273(2):643-9. PubMed ID: 7752066
[TBL] [Abstract][Full Text] [Related]
12. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure.
Golozoubova V; Strauss F; Malmlöf K
Pharmacol Biochem Behav; 2006 Apr; 83(4):517-27. PubMed ID: 16647108
[TBL] [Abstract][Full Text] [Related]
13. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers.
Kleven MS; Koek W
J Pharmacol Exp Ther; 1998 Mar; 284(3):1015-25. PubMed ID: 9495862
[TBL] [Abstract][Full Text] [Related]
15. Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine.
Cheetham SC; Viggers JA; Slater NA; Heal DJ
Neuropharmacology; 2000 Aug; 39(11):2028-35. PubMed ID: 10963746
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats.
Rowley HL; Butler SA; Prow MR; Dykes SG; Aspley S; Kilpatrick IC; Heal DJ
Synapse; 2000 Nov; 38(2):167-76. PubMed ID: 11018791
[TBL] [Abstract][Full Text] [Related]
17. Perinatal protein restriction reduces the inhibitory action of serotonin on food intake.
Lopes de Souza S; Orozco-Solis R; Grit I; Manhães de Castro R; Bolaños-Jiménez F
Eur J Neurosci; 2008 Mar; 27(6):1400-8. PubMed ID: 18331342
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine.
Liu YL; Heal DJ; Stock MJ
Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1245-53. PubMed ID: 12187403
[TBL] [Abstract][Full Text] [Related]
19. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants.
Larsen MH; Hay-Schmidt A; Rønn LC; Mikkelsen JD
Eur J Pharmacol; 2008 Jan; 578(2-3):114-22. PubMed ID: 17950272
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
Billes SK; Cowley MA
Neuropsychopharmacology; 2007 Apr; 32(4):822-34. PubMed ID: 16841072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
